Hunan Anshengmei Pharmaceutical Research Institute Co., Ltd.

Hunan Anshengmei Pharmaceutical Research Institute Co., Ltd. was established on March 6, 2017. It is a third-party experimental institution providing toxicological safety evaluation services to domestic and international organizations. Its business mainly includes early toxicity screening and toxicity prediction, single-dose toxicity tests, repeated-dose toxicity tests, reproductive toxicity tests, genotoxicity tests (including Ames, micronucleus, chromosomal aberration, mouse lymphoma assay, etc.), carcinogenicity tests, local toxicity tests, immunogenicity tests, safety pharmacology, toxicokinetic tests and other safety evaluation studies.
The company has completed the construction of 3,000 square meters of GLP-compliant animal feeding and management facilities and modern functional laboratories. It currently has a research team led by toxicology experts, with PhDs and master's degree holders as the backbone, highly skilled and with comprehensive qualities. Adhering to the purpose of "serving drug innovation and benefiting human society," aiming to improve the level of life science research and biopharmaceutical R&D, based on Hunan's characteristic resources and advantages, guaranteed by enterprise-oriented operation mechanisms, relying on science and technology, and market-oriented, the company is actively aligning with international standards to build a high-standard, large-scale, open and shared public service platform for pharmaceutical research technology.